When a drug is approved as, or as an integral part of, first line standard of care for a given disease, every patient diagnosed with that disease is supposed to receive the drug and reimbursement should be customary. Approval as part of first line standard of care for advanced primary head and neck cancer should translate into billions of dollars in sales and assure blockbuster status to Multikine. Since CEL-SCI still owns all of the major marketing rights to Multikine, our shareholders, in addition to the patients, would be the greatest beneficiaries of such a phenomenal success.
Attempts to use the power of the immune system to fight cancer date from the early 20th century observation of a New York surgeon, Dr. William B. Coley, that some sarcoma patients who suffered severe bacterial infections underwent spontaneous regression of their tumors. Due to limited knowledge of the immune system, progress in using immunotherapy was very slow. Efforts to treat cancer using immunotherapy were limited and empiric.
Advances in science, immunology and technology in the late 1970's have
made possible a more complete understanding of the molecular and cellular
components and functions of the immune system. Since then, there has been
an explosion of interest in immunotherapy and extensive efforts have been
made to develop immunotherapeutic drugs and vaccines to treat cancer.
Despite these extensive efforts, no drug or vaccine has been developed that
by itself is totally effective in maximally harnessing the power of the
immune response to fight cancer. Nevertheless, many opinion leaders still
believe that immunotherapy is the next great hope for an effect
|SOURCE CEL-SCI Corporation|
Copyright©2007 PR Newswire.
All rights reserved